{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T09:05:13Z","timestamp":1770455113676,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T00:00:00Z","timestamp":1537920000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Amgen (Europe) GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s00520-018-4473-x","type":"journal-article","created":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T18:14:51Z","timestamp":1537985691000},"page":"1449-1457","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin\u2019s lymphoma patients receiving high (>\u200920%) FN-risk chemotherapy: results from a prospective observational study"],"prefix":"10.1007","volume":"27","author":[{"given":"Jean Paul","family":"Salmon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Smakal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charisios","family":"Karanikiotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek Z.","family":"Wojtukiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohann","family":"Omnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"DeCosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Wetten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"O\u2019Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,26]]},"reference":[{"key":"4473_CR1","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3111\/13696998.2013.782034","volume":"16","author":"B Dulisse","year":"2013","unstructured":"Dulisse B, Li X, Gayle JA, Barron RL, Ernst FR, Rothman KJ, Legg JC, Kaye JA (2013) A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia. J Med Econ 16:720\u2013735","journal-title":"J Med Econ"},{"key":"4473_CR2","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258\u20132266","journal-title":"Cancer"},{"key":"4473_CR3","doi-asserted-by":"publisher","first-page":"5555","DOI":"10.1002\/cncr.25332","volume":"116","author":"GH Lyman","year":"2010","unstructured":"Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS, Yu J (2010) Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 116:5555\u20135563","journal-title":"Cancer"},{"key":"4473_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JOP.2014.001492","volume":"11","author":"D Weycker","year":"2015","unstructured":"Weycker D, Li X, Edelsberg J, Barron R, Kartashov A, Xu H, Lyman GH (2015) Risk and consequences of chemotherapy-induced febrile neutropenia in patients with metastatic solid tumors. J Oncol Pract 11:47\u201354","journal-title":"J Oncol Pract"},{"key":"4473_CR5","doi-asserted-by":"crossref","unstructured":"Loibl S, Skacel T, Nekljudova V, Luck HJ, Schwenkglenks M, Brodowicz T, Zielinski C, von Minckwitz G (2011) Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients\u2019 short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis. BMC Cancer 11:131","DOI":"10.1186\/1471-2407-11-131"},{"key":"4473_CR6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.critrevonc.2010.02.002","volume":"77","author":"H Wildiers","year":"2011","unstructured":"Wildiers H, Reiser M (2011) Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Crit Rev Oncol Hematol 77:221\u2013240","journal-title":"Crit Rev Oncol Hematol"},{"key":"4473_CR7","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1634\/theoncologist.12-12-1416","volume":"12","author":"L Balducci","year":"2007","unstructured":"Balducci L, Al-Halawani H, Charu V, Tam J, Shahin S, Dreiling L, Ershler WB (2007) Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 12:1416\u20131424","journal-title":"Oncologist"},{"key":"4473_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3816\/CCC.2010.n.013","volume":"9","author":"JR Hecht","year":"2010","unstructured":"Hecht JR, Pillai M, Gollard R, Heim W, Swan F, Patel R, Dreiling L, Mo M, Malik I (2010) A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin Colorectal Cancer 9:95\u2013101","journal-title":"Clin Colorectal Cancer"},{"key":"4473_CR9","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","volume":"23","author":"CL Vogel","year":"2005","unstructured":"Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178\u20131184","journal-title":"J Clin Oncol"},{"key":"4473_CR10","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25:3158\u20133167","journal-title":"J Clin Oncol"},{"key":"4473_CR11","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1056\/NEJM198806023182202","volume":"318","author":"JL Gabrilove","year":"1988","unstructured":"Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, Yagoda A, Fain K, Moore MAS, Clarkson B, Oettgen HF, Alton K, Welte K, Souza L (1988) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414\u20131422","journal-title":"N Engl J Med"},{"key":"4473_CR12","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/COC.0000000000000141","volume":"37","author":"L Balducci","year":"2014","unstructured":"Balducci L, Mo M, Abella E, Saven A (2014) Retrospective analysis of relative dose intensity in patients with non-Hodgkin lymphoma receiving CHOP-based chemotherapy and pegfilgrastim. Am J Clin Oncol 37:603\u2013610","journal-title":"Am J Clin Oncol"},{"key":"4473_CR13","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1093\/annonc\/mdt226","volume":"24","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff DA, Kuderer NM, Huang M, Crawford J (2013) The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 24:2475\u20132484","journal-title":"Ann Oncol"},{"key":"4473_CR14","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1200\/JCO.2012.44.6229","volume":"31","author":"MJ Aarts","year":"2013","unstructured":"Aarts MJ, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijssen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Borm GF, Tjan-Heijnen VC (2013) Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia. J Clin Oncol 31:4290\u20134296","journal-title":"J Clin Oncol"},{"key":"4473_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8\u201332","journal-title":"Eur J Cancer"},{"key":"4473_CR16","doi-asserted-by":"publisher","first-page":"914","DOI":"10.6004\/jnccn.2011.0075","volume":"9","author":"J Crawford","year":"2011","unstructured":"Crawford J, Allen J, Armitage J, Blayney DW, Cataland SR, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Steensma DP, Vadhan-Raj S, Westervelt P, Westmoreland M (2011) Myeloid growth factors. J Natl Compr Cancer Netw 9:914\u2013932","journal-title":"J Natl Compr Cancer Netw"},{"key":"4473_CR17","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J (2016) Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol 27:v111\u2013v118","journal-title":"Ann Oncol"},{"key":"4473_CR18","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33:3199\u20133212","journal-title":"J Clin Oncol"},{"key":"4473_CR19","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00520-013-2021-2","volume":"22","author":"K Krzemieniecki","year":"2014","unstructured":"Krzemieniecki K, Sevelda P, Erdkamp F, Smakal M, Schwenkglenks M, Puertas J, Trojan A, Szabo Z, Bendall K, Maenpaa J (2014) Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practice. Support Care Cancer 22:667\u2013677","journal-title":"Support Care Cancer"},{"key":"4473_CR20","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1007\/s00520-014-2184-5","volume":"22","author":"WJ Langeberg","year":"2014","unstructured":"Langeberg WJ, Siozon CC, Page JH, Morrow PK, Chia VM (2014) Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma. Support Care Cancer 22:2167\u20132175","journal-title":"Support Care Cancer"},{"key":"4473_CR21","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00520-016-3421-x","volume":"25","author":"D Weycker","year":"2017","unstructured":"Weycker D, Li X, Tzivelekis S, Atwood M, Garcia J, Li Y, Reiner M, Lyman GH (2017) Burden of chemotherapy-induced febrile neutropenia hospitalizations in US clinical practice, by use and patterns of prophylaxis with colony-stimulating factor. Support Care Cancer 25:439\u2013447","journal-title":"Support Care Cancer"},{"key":"4473_CR22","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1007\/s00520-015-3039-4","volume":"24","author":"D Weycker","year":"2016","unstructured":"Weycker D, Li X, Barron R, Li Y, Reiner M, Kartashov A, Figueredo J, Tzivelekis S, Garcia J (2016) Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice. Support Care Cancer 24:2481\u20132490","journal-title":"Support Care Cancer"},{"key":"4473_CR23","unstructured":"Amgen Ltd (2007) Neulasta Summary of Product Characteristics. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000420\/WC500025945.pdf\n                    \n                  . Accessed 19 Oct 2017"},{"key":"4473_CR24","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1007\/s00520-014-2318-9","volume":"22","author":"H Assi","year":"2014","unstructured":"Assi H, Murray J, Boyle L, Rayson D (2014) Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment. Support Care Cancer 22:3227\u20133234","journal-title":"Support Care Cancer"},{"key":"4473_CR25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ejca.2010.10.001","volume":"47","author":"J Fraser","year":"2011","unstructured":"Fraser J, Steele N, Al Zaman A, Yule A (2011) Are patients in clinical trials representative of the general population? Dose intensity and toxicities associated with FE100C-D chemotherapy in a non-trial population of node positive breast cancer patients compared with PACS-01 trial group. Eur J Cancer 47:215\u2013220","journal-title":"Eur J Cancer"},{"key":"4473_CR26","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1007\/s00520-011-1375-6","volume":"20","author":"T Younis","year":"2012","unstructured":"Younis T, Rayson D, Thompson K (2012) Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis. Support Care Cancer 20:2523\u20132530","journal-title":"Support Care Cancer"},{"key":"4473_CR27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s00508-015-0917-1","volume":"128","author":"R Madry","year":"2016","unstructured":"Madry R, Poplawska L, Haslbauer F, Safanda M, Ghizdavescu D, Benkovicova J, Csoszi T, Mihaylov G, Niepel D, Jaeger C, Frkanova I, Macovei A, Staudigl C (2016) Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy. Wien Klin Wochenschr 128:238\u2013247","journal-title":"Wien Klin Wochenschr"},{"key":"4473_CR28","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1185\/03007995.2013.781018","volume":"29","author":"M Fiegl","year":"2013","unstructured":"Fiegl M, Steger GG, Studnicka M, Eisterer W, Jaeger C, Willenbacher W (2013) Pegfilgrastim prophylaxis in patients at different levels of risk for chemotherapy-associated febrile neutropenia: an observational study. Curr Med Res Opin 29:505\u2013515","journal-title":"Curr Med Res Opin"},{"key":"4473_CR29","first-page":"214","volume":"19","author":"W Jurczak","year":"2015","unstructured":"Jurczak W, Kalinka-Warzocha E, Chmielowska E, Duchnowska R, Wojciechowska-Lampka E, Wieruszewska K (2015) Multicentre, prospective observational study of pegfilgrastim primary prophylaxis in patients at high risk of febrile neutropenia in Poland: PROFIL study. Contemp Oncol (Pozn) 19:214\u2013219","journal-title":"Contemp Oncol (Pozn)"},{"key":"4473_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.breast.2015.11.007","volume":"25","author":"J Maenpaa","year":"2016","unstructured":"Maenpaa J, Varthalitis I, Erdkamp F, Trojan A, Krzemieniecki K, Lindman H, Bendall K, Vogl FD, Verma S (2016) The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid study. Breast 25:27\u201333","journal-title":"Breast"},{"key":"4473_CR31","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1080\/03007995.2017.1386638","volume":"33","author":"D Weycker","year":"2017","unstructured":"Weycker D, Bensink M, Wu H, Doroff R, Chandler D (2017) Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis based on real-world data from 2010 to 2015. Curr Med Res Opin 33:2115\u20132120","journal-title":"Curr Med Res Opin"},{"key":"4473_CR32","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1007\/s00520-017-3842-1","volume":"25","author":"M Aapro","year":"2017","unstructured":"Aapro M, Boccia R, Leonard R, Camps C, Campone M, Choquet S, Danova M, Glaspy J, Hus I, Link H, Sliwa T, Tesch H, Valero V (2017) Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Support Care Cancer 25:3295\u20133304","journal-title":"Support Care Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-018-4473-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4473-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4473-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T23:10:05Z","timestamp":1569453005000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-018-4473-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,26]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["4473"],"URL":"https:\/\/doi.org\/10.1007\/s00520-018-4473-x","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,26]]},"assertion":[{"value":"27 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was sponsored by Amgen. All authors had full access to the study data.Lucy DeCosta, James O\u2019Kelly, Yohann Omnes and Sally Wetten are employees of and shareholders in Amgen. Charisios Karanikiotis, Martin Smakal, Jean Paul Salmon and Marek Wojtukiewicz have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"There is a plan to share data. This may include de-identified individual patient data for variables necessary to address the specific research question in an approved data-sharing request; also related data dictionaries, study protocol, statistical analysis plan, informed consent form and\/or clinical study report. Data sharing requests relating to data in this manuscript will be considered after the publication date and (1) this product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or (2) clinical development discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for these data. Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study\/studies in scope, endpoints\/outcomes of interest, statistical analysis plan, data requirements, publication plan and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labeling. A committee of internal advisors reviews requests. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and\/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the following: .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing statement"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}